Bausch Health Cos., Inc. (BHC)
8.56
-0.17
(-1.95%)
USD |
NYSE |
Nov 19, 16:00
8.565
0.00 (0.00%)
Pre-Market: 20:00
Bausch Health Cos. EPS Diluted (Quarterly) : 1.145 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.145 |
| June 30, 2026 | 0.6824 |
| March 31, 2026 | -3.817 |
| December 31, 2025 | -0.3023 |
| September 30, 2025 | 0.4767 |
| June 30, 2025 | 0.3967 |
| March 31, 2025 | -0.1569 |
| December 31, 2024 | 0.2529 |
| September 30, 2024 | -0.2307 |
| June 30, 2024 | 0.027 |
| March 31, 2024 | -0.1745 |
| December 31, 2023 | -0.1068 |
| September 30, 2023 | -1.034 |
| June 30, 2023 | 0.0708 |
| March 31, 2023 | -0.5533 |
| December 31, 2022 | -1.133 |
| September 30, 2022 | 1.098 |
| June 30, 2022 | -0.4003 |
| March 31, 2022 | -0.1912 |
| December 31, 2021 | 0.1895 |
| September 30, 2021 | 0.5165 |
| June 30, 2021 | -1.657 |
| March 31, 2021 | -1.710 |
| December 31, 2020 | -0.4305 |
| September 30, 2020 | 0.1984 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.9175 |
| March 31, 2020 | -0.4301 |
| December 31, 2019 | -4.300 |
| September 30, 2019 | -0.139 |
| June 30, 2019 | -0.4857 |
| March 31, 2019 | -0.148 |
| December 31, 2018 | -0.9832 |
| September 30, 2018 | -0.9957 |
| June 30, 2018 | -2.485 |
| March 31, 2018 | -7.360 |
| December 31, 2017 | 1.45 |
| September 30, 2017 | 3.69 |
| June 30, 2017 | -0.11 |
| March 31, 2017 | 1.79 |
| December 31, 2016 | -1.47 |
| September 30, 2016 | -3.49 |
| June 30, 2016 | -0.88 |
| March 31, 2016 | -1.08 |
| December 31, 2015 | -1.12 |
| September 30, 2015 | 0.14 |
| June 30, 2015 | -0.15 |
| March 31, 2015 | 0.28 |
| December 31, 2014 | 1.50 |
| September 30, 2014 | 0.81 |
| June 30, 2014 | 0.37 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| NervGen Pharma Corp. | -0.0426 |
| Milestone Pharmaceuticals, Inc. | -0.1831 |
| Appili Therapeutics, Inc. | -0.0099 |
| Clearmind Medicine, Inc. | -4.588 |
| Lexaria Bioscience Corp. | -1.204 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 446.00M |
| Revenue (Quarterly) | 2.941B |
| Total Expenses (Quarterly) | 2.505B |
| Enterprise Value | 22.42B |
| Gross Profit Margin (Quarterly) | 67.29% |
| Profit Margin (Quarterly) | 15.16% |
| Earnings Yield | -26.77% |
| Operating Earnings Yield | 93.92% |
| Normalized Earnings Yield | 12.48 |